Brief: Oramed Pharmaceuticals Issues Shareholder Update
09/02/2023 13:49
Feb 9 (Reuters) - Oramed Pharmaceuticals Inc ORMP.O :
* ORAMED PHARMACEUTICALS ISSUES SHAREHOLDER UPDATE
* ORAMED PHARMACEUTICALS INC - CONTINUES TO CONDUCT A
COMPREHENSIVE ANALYSIS OF DATA FROM ITS DISCONTINUED PHASE 3
ORAL INSULIN TRIALS
* ORAMED - TO EXPLORE POTENTIAL STRATEGIC ALTERNATIVES THAT
MAY
INCLUDE, BUT ARE NOT LIMITED TO, ACQUISITION, MERGER, BUSINESS
COMBINATION, OTHER DEAL
* ORAMED PHARMACEUTICALS INC - EXAMINING CO'S EXISTING
PIPELINE,
CONDUCTING COMPREHENSIVE REVIEW OF STRATEGIC ALTERNATIVES
Source text for Eikon: ID:nPnfR6JSa
Further company coverage: ORMP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oramed Pharmaceuticals
See all newsBrief: Nano Dimension Appoints Nadav Kidron To Board Of Directors To Chair Strategy And Capital Allocation Committee
Oramed Pharmaceuticals Inc expected to post earnings of 43 cents a share - Earnings Preview
Brief: Oramed And Lifeward Announce Strategic Transaction
Brief: Oramed Receives $18 Million Payment From Scilex Holdings
Brief: Oramed Reports Fiscal Third Quarter 2025 Financial Results